ASH 2022 | Challenges associated with managing chemotherapy-induced thrombocytopenia
Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, highlights the challenges associated with treating and preventing chemotherapy-induced thrombocytopenia – highlighting the trade-off between reducing chemotherapy doses to prevent thrombocytopenia and worsening patient outcomes, and commenting on the use of thrombopoietin receptor agonists in this setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Argenx: Consultancy; Novartis: Consultancy; Moderna: Consultancy; Dova: Consultancy, Research Funding; Forma: Consultancy; Rigel: Consultancy; Amgen: Research Funding; Sobi: Consultancy, Research Funding; Agios: Consultancy, Research Funding.
